The US Medicare agency is casting a very broad net to ensure that all versions of the same active ingredient are included in the price negotiation process, regardless of differences in dosage form, branding, indications, or regulatory pathway.
In an implementation guidance released on 15 March, the Centers for Medicare & Medicaid Services makes clear that it...







